Viatris Inc.
Clinical trials sponsored by Viatris Inc., explained in plain language.
Global healthcare company offering a wide range of branded and generic medicines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Does gabapentin make oxycodone more likable? a trial asks Results expected Jan 2027 (estimated)
- New allergy spray trial aims to help teens breathe easier Results expected Mar 2027 (estimated)
-
New allergy spray trial aims to help teens breathe easier
Symptom relief Recruiting nowThis study tests if Dymista nasal spray safely eases allergy symptoms like sneezing, stuffy nose, and itchy eyes in Chinese teenagers aged 12 to 17. About 100 participants will use the spray twice daily for two weeks. The goal is to see if symptoms improve, not to cure allergies.
Phase 4 • Sponsor: Viatris Inc. • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
Does gabapentin make oxycodone more likable? a trial asks
Knowledge-focused Recruiting nowResearchers are studying whether gabapentin, a drug used for nerve pain and seizures, changes how much people like the effects of oxycodone, a prescription opioid. The trial enrolls healthy adults aged 18 to 55 who have used opioids recreationally but are not dependent on drugs. …
Phase 4 • Sponsor: Viatris Inc. • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC